Comprehensive Panel (LPP+™) and Basic Panel (LPP™)
LPP+ with Homocysteine and High Sensitivity C-Reactive Protein and Insulin
SpectraCell’s LPP™ test is the most advanced lipoprotein test currently available. Unlike traditional cholesterol tests, Spectracell’s LPP™ directly measures both the density (size) and number of several classes of lipoprotein particles, including critical risk factors as cited by the National Cholesterol Education Program, giving an accurate assessment of cardiovascular risk.
Many patients understand that not all cholesterol is the same. There is the “good” HDL (High Density Lipoprotein) cholesterol and the “bad” LDL (Low Density Lipoprotein) cholesterol. However, different types of HDL and LDL exist and some are much more dangerous than others. The LPP™ test determines the specific number of particles in each lipoprotein subclass (HDL and LDL) for a much more accurate assessment of risk. For example, the LPP™ test measures RLP (remnant lipoprotein) and Lp(a), both very atherogenic, but with very different effective treatment options. A standard cholesterol test does not give this information, putting the clinician at a disadvantage when deciding the most effective clinical treatment for their patient.
Moreover, since it is the actual lipoproteins (not the cholesterol inside them) that contribute to cardiovascular disease, the LPP™ test is more advanced than standard cholesterol testing or other advanced cholesterol testing technologies. The LPP™ test measures the lipoprotein particles directly, giving a precise evaluation of their density (size). Armed with this information, a clinician is empowered to make the best possible decisions regarding their patients’ care when it comes to reducing cardiovascular risk.